Aartselaar

Epstein-Barr Virus (EBV) infects about 95% of adults worldwide and can cause various diseases, including infectious mononucleosis and chronic fatigue syndrome. Usually, the infection shows no symptoms due to an effective immune response. Currently, there is no treatment that eliminates EBV, and care focuses on managing symptoms such as pain. This study aims to evaluate the effectiveness of two drugs, 2LEBVAE and 2LXFSAE, compared to a placebo in reducing fatigue and other symptoms in patients with EBV infections. Participants will receive either 2LEBVAE, 2LXFSAE, or a placebo, following the same treatment schedule. Each day, they will take one capsule on an empty stomach, 15 to 30 minutes before breakfast, in numerical order from capsule 1 through 10. After finishing capsule 10, they continue with capsule 1 of the next blister pack. This daily treatment will continue for 6 months without interruption. During the study, participants will be evaluated using the Multidimensional Fatigue Inventory-20 questionnaire to measure general fatigue at the end of the 6-month treatment. Researchers will monitor symptoms and treatment adherence throughout the study. The goal is to gather additional information on the effectiveness of these drugs in treating acute and chronic EBV infections and improving patient fatigue and other related symptoms.